First Time Loading...
M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 22.18 CNY 1.09% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. [ Read More ]

The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 32.58 CNY. Compared to the current market price of 22.18 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 32%.

Key Points:
Intrinsic Value
Base Case
32.58 CNY
Undervaluation 32%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
Mayinglong Pharmaceutical Group Co Ltd

Backtest Mayinglong Pharmaceutical Group Co Ltd Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Mayinglong Pharmaceutical Group Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Mayinglong Pharmaceutical Group Co Ltd's business.

What risks and challenges
does Mayinglong Pharmaceutical Group Co Ltd face in the near future?

Summarize the latest earnings report
of Mayinglong Pharmaceutical Group Co Ltd.

Provide P/E
for Mayinglong Pharmaceutical Group Co Ltd and its competitors.

Financials

Balance Sheet Decomposition
Mayinglong Pharmaceutical Group Co Ltd

Current Assets 4.2B
Cash & Short-Term Investments 3B
Receivables 648.8m
Other Current Assets 635.9m
Non-Current Assets 871.3m
Long-Term Investments 153.2m
PP&E 536.4m
Intangibles 114.1m
Other Non-Current Assets 67.5m
Current Liabilities 788.1m
Accounts Payable 174.6m
Accrued Liabilities 101.7m
Short-Term Debt 173.1m
Other Current Liabilities 338.7m
Non-Current Liabilities 732.2m
Long-Term Debt 516.3m
Other Non-Current Liabilities 216m
Efficiency

Earnings Waterfall
Mayinglong Pharmaceutical Group Co Ltd

Revenue
3.2B CNY
Cost of Revenue
-1.7B CNY
Gross Profit
1.5B CNY
Operating Expenses
-995.9m CNY
Operating Income
456.9m CNY
Other Expenses
24.5m CNY
Net Income
481.3m CNY

Free Cash Flow Analysis
Mayinglong Pharmaceutical Group Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Mayinglong Pharmaceutical Group Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROIC
Positive Free Cash Flow
Positive 3-Year Average ROE
58/100
Profitability
Score

Mayinglong Pharmaceutical Group Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Mayinglong Pharmaceutical Group Co Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
85/100
Solvency
Score

Mayinglong Pharmaceutical Group Co Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Mayinglong Pharmaceutical Group Co Ltd

Wall Street analysts forecast Mayinglong Pharmaceutical Group Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Mayinglong Pharmaceutical Group Co Ltd is 20.45 CNY .

Lowest
Price Target
Not Available
Average
Price Target
20.45 CNY
8% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Mayinglong Pharmaceutical Group Co Ltd

1M 1M
-3%
6M 6M
-4%
1Y 1Y
-14%
3Y 3Y
+23%
5Y 5Y
+46%
10Y 10Y
+96%
Annual Price Range
22.18
52w Low
21.01
52w High
30.95
Price Metrics
Average Annual Return 13.07%
Standard Deviation of Annual Returns 26.53%
Max Drawdown -44%
Shares Statistics
Market Capitalization 9.6B CNY
Shares Outstanding 431 053 891
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Mayinglong Pharmaceutical Group Co Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

9.6B CNY

Dividend Yield

1.57%

Description

Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei and currently employs 3,208 full-time employees. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.

Contact

HUBEI
Wuhan
No. 100, Nanhu Zhoujiawan, Wuchang
+862787291519
http://www.mayinglong.cn

IPO

2004-05-17

Employees

3 208

Officers

GM & Director
Mr. Youzhang Xia
Financial Director
Mr. Bing Wang
Deputy GM & Secretary to the Board of Directors
Ms. Qian Ma
Accounting Supervisor
Tao Mao
Deputy GM & Director
Mr. Ping An Liu

See Also

Discover More
What is the Intrinsic Value of one Mayinglong Pharmaceutical Group Co Ltd stock?

The intrinsic value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 32.58 CNY.

Is Mayinglong Pharmaceutical Group Co Ltd stock undervalued or overvalued?

Compared to the current market price of 22.18 CNY, Mayinglong Pharmaceutical Group Co Ltd is Undervalued by 32%.